Insulet Corp
NASDAQ:PODD
Insulet Corp
Net Income (Common)
Insulet Corp
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Insulet Corp
NASDAQ:PODD
|
Net Income (Common)
$418.3m
|
CAGR 3-Years
192%
|
CAGR 5-Years
105%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Net Income (Common)
$1.7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
18%
|
CAGR 10-Years
4%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Net Income (Common)
$1.9B
|
CAGR 3-Years
23%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
Stryker Corp
NYSE:SYK
|
Net Income (Common)
$3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
19%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Net Income (Common)
$13.4B
|
CAGR 3-Years
24%
|
CAGR 5-Years
29%
|
CAGR 10-Years
19%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Net Income (Common)
$2.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
19%
|
|
Insulet Corp
Glance View
Insulet Corporation has carved out a significant niche in the medical device industry, distinguishing itself through its innovative approach to diabetes management. The company is best known for its Omnipod Insulin Management System, a discreet, tubeless insulin pump that provides a solution for individuals with diabetes seeking an alternative to traditional insulin delivery methods. Unlike conventional pumps that require cumbersome tubes and significant patient involvement, the Omnipod system offers ease and convenience, allowing users more freedom and flexibility in their daily lives. The system operates via a small wearable pod that delivers insulin over several days, which users control remotely, removing much of the hassle associated with managing diabetes. Insulet generates revenue by selling these pods and the associated Personal Diabetes Manager (PDM) devices, which together comprise the entire system. Customers typically purchase pods on a recurring basis, similar to a subscription model, which creates a steady stream of revenue for the company. The business model emphasizes continuous growth by expanding its user base and improving its technology to remain at the forefront of patient-centric diabetes care. Insulet's strategic focus on the needs of its users and commitment to refining their health technology has enabled it to build a sustainable business that addresses a critical healthcare challenge while also delivering consistent financial performance.
See Also
What is Insulet Corp's Net Income (Common)?
Net Income (Common)
418.3m
USD
Based on the financial report for Dec 31, 2024, Insulet Corp's Net Income (Common) amounts to 418.3m USD.
What is Insulet Corp's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
105%
Over the last year, the Net Income (Common) growth was 103%. The average annual Net Income (Common) growth rates for Insulet Corp have been 192% over the past three years , 105% over the past five years .
You don't have any saved screeners yet